Mesoblast Limited (MESO) Given a $14.00 Price Target by Maxim Group Analysts
Mesoblast Limited (NASDAQ:MESO) has been assigned a $14.00 target price by investment analysts at Maxim Group in a note issued to investors on Wednesday. The brokerage presently has a “buy” rating on the stock. Maxim Group’s price target suggests a potential upside of 88.93% from the stock’s previous close.
A number of other analysts have also commented on the company. Zacks Investment Research lowered Mesoblast Limited from a “buy” rating to a “sell” rating in a research note on Wednesday, May 17th. Cantor Fitzgerald started coverage on Mesoblast Limited in a research note on Wednesday, June 7th. They set a “buy” rating and a $20.00 price objective on the stock. Credit Suisse Group set a $11.00 price objective on Mesoblast Limited and gave the company a “hold” rating in a research note on Tuesday, July 18th. Finally, BidaskClub lowered Mesoblast Limited from a “sell” rating to a “strong sell” rating in a research note on Friday, July 28th. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating and two have given a buy rating to the company’s stock. The company has a consensus rating of “Hold” and a consensus price target of $12.70.
Mesoblast Limited (NASDAQ MESO) opened at 7.41 on Wednesday. The stock’s market cap is $589.42 million. Mesoblast Limited has a 12-month low of $4.01 and a 12-month high of $12.50. The stock’s 50 day moving average price is $7.40 and its 200 day moving average price is $8.20.
A hedge fund recently raised its stake in Mesoblast Limited stock. Princeton Capital Management Inc. raised its stake in Mesoblast Limited (NASDAQ:MESO) by 15.5% during the first quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 155,700 shares of the company’s stock after buying an additional 20,945 shares during the period. Princeton Capital Management Inc. owned approximately 0.20% of Mesoblast Limited worth $1,398,000 at the end of the most recent reporting period. 2.92% of the stock is owned by institutional investors.
About Mesoblast Limited
Receive News & Stock Ratings for Mesoblast Limited Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mesoblast Limited and related stocks with our FREE daily email newsletter.